losartan has been researched along with Ischemia in 24 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aims of the present study were to determine the effects and mechanisms of angiotensin II (Ang II) on leukocyte-endothelium interactions and the role of Ang II in a novel model of ischemia/reperfusion (I/R) in the mouse colon." | 7.72 | Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. ( Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y, 2004) |
| " To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)." | 7.70 | Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998) |
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 7.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion." | 5.32 | Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004) |
| "Twenty four male Wistar rats were randomly divided into four groups as follow: diabetic sham; diabetic sham + losartan (15 mg/kg/day); diabetic hindlimb ischemia; diabetic hindlimb ischemia + losartan." | 3.80 | Limbs' postischemic revascularization is not improved by losartan treatment in diabetic rats. ( Fallahzadeh, A; Khazaei, M, 2014) |
| " Hindlimb ischemia was induced in wild-type (WT), Cx40(-/-), and losartan-treated Cx40(-/-) mice by using surgical procedures that either maintained (mild surgery) or compromised (severe surgery) perfusion of major collateral vessels supplying the distal limb." | 3.79 | Compromised regulation of tissue perfusion and arteriogenesis limit, in an AT1R-independent fashion, recovery of ischemic tissue in Cx40(-/-) mice. ( Angelov, SN; Burt, JM; Fang, JS; Simon, AM, 2013) |
| " Ischemia was induced by right femoral artery ligature in Wistar Kyoto rats (WKY) or spontaneously hypertensive rats (SHR) treated with or without angiotensin-converting enzyme inhibitor (Perindopril, 0." | 3.74 | Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents. ( Cochain, C; Duriez, M; Lévy, BI; Loinard, C; Mees, B; Silvestre, JS; Vilar, J; You, D, 2008) |
| "The aim of our study was to investigate the changes in the early stages (at weeks 2 and 4) of experimental acute renal failure after short-time ischemia-reperfusion (I/R) compared with the impact of Losartan." | 3.73 | Morphological changes in experimental postischemic rat kidney. A pilot study. ( Arend, A; Aunapuu, M; Kühnel, W; Ots, M; Pechter, U, 2005) |
| "The aims of the present study were to determine the effects and mechanisms of angiotensin II (Ang II) on leukocyte-endothelium interactions and the role of Ang II in a novel model of ischemia/reperfusion (I/R) in the mouse colon." | 3.72 | Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon. ( Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y, 2004) |
| " To determine if the TI injury accompanying cyclosporine A (CsA) nephropathy was associated with accelerated apoptosis and ischemia, we treated rats for five weeks with CsA with or without losartan (to block angiotensin II type 1 receptor), or hydralazine/furosemide (H/F) (protocol #1)." | 3.70 | Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. ( Andoh, TF; Bennett, WM; Couser, WG; Johnson, RJ; Pichler, RH; Shankland, SJ; Thomas, SE, 1998) |
| "We hypothesized that angiotensin II, a potent vasoconstrictor, is involved in the occurrence of hepatic ischemia after burn and sepsis, and that administration of angiotensin II antagonist DuP753 would ameliorate this process." | 3.70 | Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II. ( Herndon, DN; Tadros, T; Traber, DL, 2000) |
| "Most patients with systemic sclerosis (SSc) have Raynaud's phenomenon (RP), which is often more severe than idiopathic RP." | 2.41 | Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. ( Fenlon, D; Pope, JE; Shea, B; Thompson, AE; Welch, V, 2001) |
| "Losartan pretreated-rats presented diminished FN abundance in homogenates of cortex tissue from ischemic rats with or without reperfusion." | 1.32 | Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function. ( Barrilli, A; Elías, MM; Menacho, M; Molinas, S; Petrini, G, 2004) |
| "Pretreatment of enalapril and losartan did not prevent the reduction in GFR, indicating that angiotensin II was not involved." | 1.31 | Mechanism of reduced GFR in rabbits with ischemic acute renal failure. ( Cho, SI; Jung, JS; Kim, BS; Kim, SJ; Kim, YK; Lim, YT; Woo, JS, 2000) |
| "Proteinuria was markedly reduced in both strains by L." | 1.29 | Losartan protects the rat kidney from ischemic injury. ( Cervenka, L; Heller, J; Hellerová, S; Kramer, HJ, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (16.67) | 18.2507 |
| 2000's | 13 (54.17) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warrington, JP | 1 |
| Fan, F | 1 |
| Duncan, J | 1 |
| Cunningham, MW | 1 |
| LaMarca, BB | 1 |
| Dechend, R | 3 |
| Wallukat, G | 3 |
| Roman, RJ | 1 |
| Drummond, HA | 1 |
| Granger, JP | 2 |
| Ryan, MJ | 1 |
| Soni, H | 1 |
| Peixoto-Neves, D | 1 |
| Olushoga, MA | 1 |
| Adebiyi, A | 1 |
| Fallahzadeh, A | 1 |
| Khazaei, M | 1 |
| Srisawat, U | 1 |
| Kongrat, S | 1 |
| Muanprasat, C | 1 |
| Chatsudthipong, V | 1 |
| LaMarca, B | 2 |
| Llinas, M | 1 |
| Herse, F | 2 |
| Oztürk, CN | 1 |
| Tezel, E | 1 |
| Yalçın, O | 1 |
| Novotny, SR | 1 |
| Wallace, K | 1 |
| Heath, J | 1 |
| Moseley, J | 1 |
| Dhillon, P | 1 |
| Weimer, A | 1 |
| Wenzel, K | 1 |
| Martin, JN | 1 |
| Fang, JS | 1 |
| Angelov, SN | 1 |
| Simon, AM | 1 |
| Burt, JM | 1 |
| Riaz, AA | 1 |
| Wang, Y | 1 |
| Schramm, R | 1 |
| Sato, T | 1 |
| Menger, MD | 1 |
| Jeppsson, B | 1 |
| Thorlacius, H | 1 |
| Singh, D | 1 |
| Chopra, K | 1 |
| Barrilli, A | 1 |
| Molinas, S | 1 |
| Petrini, G | 1 |
| Menacho, M | 1 |
| Elías, MM | 1 |
| Aunapuu, M | 1 |
| Pechter, U | 1 |
| Kühnel, W | 1 |
| Ots, M | 1 |
| Arend, A | 1 |
| Tokuyama, H | 1 |
| Kelly, DJ | 1 |
| Zhang, Y | 1 |
| Gow, RM | 1 |
| Gilbert, RE | 1 |
| You, D | 1 |
| Cochain, C | 1 |
| Loinard, C | 1 |
| Vilar, J | 1 |
| Mees, B | 1 |
| Duriez, M | 1 |
| Lévy, BI | 1 |
| Silvestre, JS | 1 |
| Nelissen-Vrancken, HJ | 1 |
| Boudier, HA | 1 |
| Daemen, MJ | 1 |
| Smits, JF | 1 |
| Heller, J | 2 |
| Kramer, HJ | 1 |
| Cervenka, L | 2 |
| Hellerová, S | 1 |
| Kontogiannis, J | 1 |
| Burns, KD | 1 |
| Thomas, SE | 1 |
| Andoh, TF | 1 |
| Pichler, RH | 1 |
| Shankland, SJ | 1 |
| Couser, WG | 1 |
| Bennett, WM | 1 |
| Johnson, RJ | 1 |
| Kim, SJ | 1 |
| Lim, YT | 1 |
| Kim, BS | 1 |
| Cho, SI | 1 |
| Woo, JS | 1 |
| Jung, JS | 1 |
| Kim, YK | 1 |
| Pagtalunan, ME | 1 |
| Olson, JL | 1 |
| Meyer, TW | 1 |
| Tadros, T | 1 |
| Traber, DL | 1 |
| Herndon, DN | 1 |
| Spatenka, J | 1 |
| Havlícková, J | 1 |
| Thompson, AE | 1 |
| Shea, B | 1 |
| Welch, V | 1 |
| Fenlon, D | 1 |
| Pope, JE | 1 |
| Emanueli, C | 1 |
| Salis, MB | 1 |
| Stacca, T | 1 |
| Pinna, A | 1 |
| Gaspa, L | 1 |
| Madeddu, P | 1 |
| Maddeddu, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.[NCT03211325] | 29 participants (Actual) | Interventional | 2016-10-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Ischemia
| Article | Year |
|---|---|
Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
Topics: Calcium Channel Blockers; Cross-Over Studies; Humans; Iloprost; Injections, Intravenous; Ischemia; L | 2001 |
23 other studies available for losartan and Ischemia
| Article | Year |
|---|---|
The angiotensin II type I receptor contributes to impaired cerebral blood flow autoregulation caused by placental ischemia in pregnant rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cerebrovascular Circulation; Female; Homeostasis; | 2019 |
Pharmacological inhibition of TRPV4 channels protects against ischemia-reperfusion-induced renal insufficiency in neonatal pigs.
Topics: Animals; Animals, Newborn; Blood Pressure; Glomerular Filtration Rate; Ischemia; Kidney; Losartan; M | 2019 |
Limbs' postischemic revascularization is not improved by losartan treatment in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Capillaries; Diabetes Mellitus, Exp | 2014 |
Losartan and Sodium Nitroprusside Effectively Protect against Renal Impairments after Ischemia and Reperfusion in Rats.
Topics: Adenosine Triphosphatases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arginin | 2015 |
Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Blood Pressure; Female; Hypertensi | 2008 |
Evaluation of the effects of losartan on a random pattern skin flap model in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Dermatologic Surgical Procedures; Ischemia; Losart | 2011 |
Activating autoantibodies to the angiotensin II type I receptor play an important role in mediating hypertension in response to adoptive transfer of CD4+ T lymphocytes from placental ischemic rats.
Topics: Adoptive Transfer; Angiotensin II Type 1 Receptor Blockers; Animals; Autoantibodies; Blood Pressure; | 2012 |
Compromised regulation of tissue perfusion and arteriogenesis limit, in an AT1R-independent fashion, recovery of ischemic tissue in Cx40(-/-) mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Connexins; Gap Junction alpha-5 Protein; Hindlimb; | 2013 |
Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon.
Topics: Allopurinol; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Capillaries; Captopr | 2004 |
Evidence of the role of angiotensin AT(1) receptors in remote renal preconditioning of myocardium.
Topics: Angiotensin II; Animals; Blood Pressure; Body Temperature; Coronary Vessels; Disease Models, Animal; | 2004 |
Losartan reverses fibrotic changes in cortical renal tissue induced by ischemia or ischemia-reperfusion without changes in renal function.
Topics: Animals; Blood Urea Nitrogen; Fibronectins; Fibrosis; Glomerular Filtration Rate; Ischemia; Kidney C | 2004 |
Morphological changes in experimental postischemic rat kidney. A pilot study.
Topics: Animals; Antihypertensive Agents; Basement Membrane; Blood Pressure; Disease Models, Animal; Ischemi | 2005 |
Macrophage infiltration and cellular proliferation in the non-ischemic kidney and heart following prolonged unilateral renal ischemia.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Movement; Cell Proliferation; | 2007 |
Hypertension impairs postnatal vasculogenesis: role of antihypertensive agents.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Bone Marrow Cells; Cell Differentiation; Disease M | 2008 |
Antihypertensive therapy and adaptive mechanisms in peripheral ischemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 1993 |
Losartan protects the rat kidney from ischemic injury.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Creatinine; Hypertension; Imid | 1996 |
Role of AT1 angiotensin II receptors in renal ischemic injury.
Topics: Angiotensin II; Angiotensinogen; Animals; Creatinine; Ischemia; Kidney; Kidney Cortex; Kidney Medull | 1998 |
Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; Argin | 1998 |
Mechanism of reduced GFR in rabbits with ischemic acute renal failure.
Topics: Acute Kidney Injury; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihyperten | 2000 |
Contribution of angiotensin II to late renal injury after acute ischemia.
Topics: Acute Disease; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Disease Progressio | 2000 |
Trauma- and sepsis-induced hepatic ischemia and reperfusion injury: role of angiotensin II.
Topics: Analysis of Variance; Angiotensin II; Animals; Burns; Drug Evaluation, Preclinical; Escherichia coli | 2000 |
[Experimental ischemic renal injury--effect of surgical technique and the protective effect of a nonpeptide angiotensin II antagonist (losartan)].
Topics: Angiotensin II; Animals; Creatinine; Ischemia; Kidney; Losartan; Male; Protective Agents; Rats; Rats | 2000 |
Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2002 |